Skip to content
3B BlackBio DX logo

3B BlackBio DX

3BBLACKBIO NSE
₹1,340.00 down 23.00 (1.69%)
Market Cap
₹1,150 Cr
P/E
20.71

3B BlackBio DX (3BBLACKBIO) share price was ₹1,363.00 at the 28 Oct 2026 close; market capitalisation ₹1,170 Cr; P/E (TTM) 21.07; sector Healthcare Services. The share price rose 2.9% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue rose 50.7% year on year to ₹33.49 Cr and net profit fell 29.0% year on year to ₹8.98 Cr (compared with Jun 2025). Promoters held 40.95% of 3B BlackBio DX in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 69/100 (Strong) as of 28 Oct 2026.

Close 28 Oct 2026 ₹1,363.00 +6.30 +0.46% 1Y

Key Fundamentals

MicrocapHealthcare ServicesHealthcare
Market Cap
₹1,150 Cr
P/E (TTM)
20.71
EBITDA
₹56.78 Cr
Return on Equity
17.6%
Debt to Equity
0.01
Book Value
₹377.96
EPS (TTM)
₹64.70
52W High
₹1,750.00
52W Low
₹1,085.00

Price-based figures as of 29 Oct 2026, 10:55 IST · EPS basis: Consolidated · TTM

Peer Comparison

Healthcare › Healthcare Services › Healthcare Service Provider

Dr Lal Pathlabs
₹1,906.5058.9532,000 Cr12.760.26%20.06%25.67%2,996 Cr545 Cr
Vijaya Diagnostic Centre
₹1,438.9078.9314,820 Cr15.480.14%18.07%19.22%879 Cr187 Cr
Metropolis Healthcare
₹549.1056.4311,388 Cr7.580.91%12.54%15.73%1,733 Cr203 Cr
Thyrocare Technologies
₹514.6546.458,191 Cr15.982.84%27.79%33.84%894 Cr176 Cr
Nephrocare Health Services
₹630.30150.436,338 Cr5.680.00%6.88%13.46%1,079 Cr85 Cr
Suraksha Diagnostic
₹318.5546.301,659 Cr6.780.16%12.90%14.70%329 Cr35 Cr
Krsnaa Diagnostics
₹496.0516.271,609 Cr1.640.40%10.35%10.64%862 Cr98 Cr
3B BlackBio DX (this company)
₹1,340.0020.711,150 Cr3.550.36%17.60%23.13%181 Cr56 Cr
Median 8 companies₹589.7051.447,265 Cr7.180.31%15.25%17.48%887 Cr137 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

69 Strong
Overall score

Data confidence 100/100

Category scores

Quality Strong 76
Returns, margins, earnings quality 22% weight
Valuation Strong 70
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Strong 91
Solvency, leverage, coverage 9% weight
Momentum Weak 43
Trend strength, vol-adjusted 12% weight
Ownership Average 55
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company's median sales growth is 21.9% of last 10 years

Weaknesses

1
  • Earnings include an other income of Rs.27.4 Cr.

Technical Indicators

Oscillators

Bearish

Bearish
2
Neutral
7
Bullish
0

Overall

Bearish

Bearish
10
Neutral
7
Bullish
2

Moving Averages

Bearish

Bearish
8
Neutral
0
Bullish
2

Growth Rate

Revenue Growth
27.17% lower than 3Y

change over 1 year

Net Income Growth
27.51% lower than 3Y

change over 1 year

Cash Flow Change
60.89%

change over 1 year

EBITDA Margin Change
-41.99%

change over 1 year Operating margin 25.44% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
14.28
19.18
17.67
23
19.43
29.15
25.39
22.5
22.23
33.9
50.35
35.43
33.49
Expenses
7.84
11.39
8.8
13.12
8.48
12.98
10.32
14.58
10.4
19.17
28.63
26.94
24.97
Operating Profit
6.44
7.79
8.87
9.88
10.95
16.17
15.07
7.92
11.83
14.73
21.72
8.49
8.52
OPM %
45.1%
40.62%
50.2%
42.96%
56.36%
55.47%
59.35%
35.2%
53.22%
43.45%
43.14%
23.96%
25.44%
Other Income
2.96
2.75
2.63
4.19
3.69
3.44
3.01
4.94
4.32
5.51
5.59
10.15
6.14
Interest
0.02
0.04
0.03
0.04
0.01
0.03
0.02
0.04
0.01
0.04
0.09
0.1
0.1
Depreciation
0.19
0.24
0.32
0.3
0.27
0.27
0.27
0.28
0.28
0.58
0.38
3.89
1.34
PBT
9.19
10.26
11.15
13.73
14.36
19.31
17.79
12.54
15.86
19.62
26.84
14.65
13.22
Tax %
21.55%
26.02%
23.68%
35.98%
21.31%
22.99%
24.17%
35.89%
20.3%
23.34%
16.39%
33.11%
32.07%
Net Profit
7.21
7.58
8.51
8.79
11.3
14.87
13.49
8.04
12.65
15.04
22.44
9.81
8.98
EPS (₹)
9.71
10.46
10.16
10.33
12.97
17.07
15.61
9.79
14.67
17.14
25.32
11.14
11.1
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
19
17
16
23
23
29
227
81
62
74
96
142
153
Expenses
18
16
14
18
16
20
77
44
33
41
46
85
100
Operating Profit
1
2
3
5
7
9
150
37
29
33
50
57
53
OPM %
7%
9%
16%
23%
31%
32%
66%
46%
47%
44%
52%
40%
35%
Other Income
0
0
0
0
1
2
3
7
7
13
15
26
27
Interest
1
1
1
1
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
1
1
1
1
1
1
1
5
6
PBT
0
0
1
5
7
10
152
43
35
44
64
77
74
Tax %
23%
23%
19%
24%
25%
23%
25%
26%
27%
28%
25%
22%
—
Net Profit
0
0
1
3
5
8
114
32
26
32
48
60
56
EPS (₹)
0.36
0.51
1.76
5.35
8.18
10.24
152
42.89
34.55
37.4
55.57
68.27
64.7
Div. Payout %
0%
0%
17%
9%
6%
7%
6%
24%
8%
8%
7%
7%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6
6
6
6
6
7
7
7
9
9
9
9
Reserves
4
4
5
12
16
25
125
146
185
214
260
316
Borrowings
8
8
9
6
6
4
2
3
2
1
0
3
Other Liabilities
7
6
6
6
8
9
59
37
19
24
27
51
Total Liabilities
25
24
26
30
36
45
194
192
214
248
296
378
Fixed Assets
4
3
3
4
4
4
5
7
8
7
7
28
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0
0
0
0
0
1
59
93
92
117
156
158
Other Assets
21
21
22
26
32
40
130
93
114
123
132
193
Total Assets
25
24
26
30
36
45
194
192
214
248
296
378
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0
1
1
2
4
7
98
37
20
27
43
52
Investing
0
0
0
-1
-1
-1
-70
-28
15
-20
-33
-24
Financing
0
-1
0
0
-1
1
-2
-15
-5
-4
-3
-1
Net Cash Flow
0
0
0
1
2
7
26
-6
30
3
7
28
Free Cash Flow
0
1
0
1
3
6
96
35
18
26
42
27
CFO/EBITDA
23
69
36
52
71
101
90
129
100
115
116
121
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
262
283
321
259
290
252
56
136
200
179
138
129
Inventory Days
145
143
175
—
—
—
—
—
164
141
124
187
Days Payable
218
203
186
—
—
—
—
—
69
66
28
70
Cash Conversion Cycle
188
223
310
259
290
252
56
136
296
253
235
245
Working Capital Days
175
205
247
253
287
275
65
162
241
215
169
143
ROCE %
7%
7%
13%
24%
28%
31%
162%
27%
19%
21%
26%
25%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view 3B BlackBio DX insights

43 extracted metrics + investor summaries across FY13–FY27.

Shareholding Pattern

DIIs2.33%Promot.40.95%FIIs2.46%Others17.21%Public37.06%As ofSep 2026

Documents

Frequently Asked Questions about 3B BlackBio DX

What does 3B Blackbio DX Ltd do?
Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]
Where is 3B Blackbio DX Ltd (3BBLACKBIO) listed?
3B Blackbio DX Ltd trades as 3BBLACKBIO on the NSE and under code 532067 on the BSE.
Which sector does 3B Blackbio DX Ltd belong to?
3B Blackbio DX Ltd is classified under the Healthcare Services sector, in the Healthcare Service Provider industry.
What is the market capitalisation of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd has a market capitalisation of ₹1,150 Cr as of 29 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd trades at a PE ratio of 20.71 as of 29 Oct 2026, on earnings per share of ₹64.7, against a book value of ₹377.96 per share.
What is the 52-week high and low of 3B Blackbio DX Ltd?
Over the last 52 weeks 3B Blackbio DX Ltd has traded between ₹1,085 and ₹1,750 as of 29 Oct 2026.
Does 3B Blackbio DX Ltd pay dividends?
3B Blackbio DX Ltd has a dividend yield of 0.37%.
What is the Return on Equity (ROE) of 3B Blackbio DX Ltd?
3B Blackbio DX Ltd reported a return on equity of 17.60%. Its debt-to-equity ratio is 0.01.

Company Information

Incorporated in 2011, 3B BlackBio Dx Ltd manufactures and exports PCR based Molecular Diagnostic kits, PCR Enzymes & PCR Reagents, and agrochemical-based products[1]

Website kilpest.com
Listed 2026-04-20
Face Value ₹ 10
Shares Outstanding 85,82,670

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/532067.md for 3B Blackbio DX Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month